Theresa L. Werner, MD

Journal Article

1. Liu J, Berchuck A, Backes FJ, Cohen J, Grisham R, Leath CA, Martin L, Matei D, Miller DS, Robertson S, Barroilhet L, Uppal S, Hendrickson AW, Gershenson DM, Gray HJ, Hakam A, Jain A, Konecny GE, Moroney J, Ratner E, Schorge J, Thaker PH, Werner TL, Zsiros E, Behbakht K, Chen LM, DeRosa M, Eisenhauer EL, Leiserowitz G, Litkouhi B, McHale M, Percac-Lima S, Rodabaugh K, Vargas R, Jones F, Kovach E, Hang L, Ramakrishnan S, Alvarez RD, Armstrong DK (2024). NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024. J Natl Compr Canc Netw, 22(8), 512-519. (Read full article)
2. Pant S, Cho BC, Kyriakopoulos CE, Spira A, Tannir N, Werner TL, Yan X, Neuteboom S, Chao R, Goel S (2024). Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer. Invest New Drugs. (Read full article)
3. Pitiyarachchi O, Ansell PJ, Coleman RL, Dinh MH, Holman L, Leath CA 3rd, Werner T, DiSilvestro P, Morgan M, Tew W, Lee C, Cunningham M, Newton M, Edraki B, Lim P, Barlin J, Spirtos NM, Tewari KS, Edelson M, Reid T, Carlson J, Friedlander M (2024). Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over. Gynecol Oncol, 187, 221-226. (Read full article)
4. Kang YK, Ryu MH, Hong YS, Choi CM, Kim TW, Ryoo BY, Kim JE, Weis JR, Kingsford R, Park CH, Jang S, McGinn A, Werner TL, Sharma S (2024). Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors. Cancer Res Treat. (Read full article)
5. Hutten RJ, Weil CR, King AJ, Barney B, Bylund CL, Fagerlin A, Gaffney DK, Gill D, Scherer L, Suneja G, Tward JD, Warner EL, Werner TL, Whipple G, Evans J, Johnson SB (2023). Multi-Institutional Analysis of Cancer Patient Exposure, Perceptions, and Trust in Information Sources Regarding Complementary and Alternative Medicine. JCO Oncol Pract, 19(11), OP2300179. (Read full article)
6. George TJ, Lin TL, Adrales Bentz T, Grant S, Houston CM, Nashawati MA, Pappu B, Peck H, Zafirovski A, Kerstann K, LoRusso P, Schnatterly A, Hofacker J, Cameron K, Honeycutt H, Werner TL (2022). Quantifying the impact of the COVID-19 pandemic on cancer center clinical trial operations. JNCI Cancer Spectr, 7(4). (Read full article)
7. Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Chitiyo VC, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA III, Leiserowitz G, Liu J, Martin L, Matei D, McHale M, McLean K, Miller DS, Percac-Lima S, Remmenga SW, Schorge J, Stewart D, Thaker PH, Vargas R, Hendrickson AW, Werner TL, Zsiros E, Dwyer MA, Hang L (2022). NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022. J Natl Compr Canc Netw, 20(9), 972-980. (Read full article)
8. Bauer T, Cho BC, Heist R, Bazhenova L, Werner T, Goel S, Kim DW, Adkins D, Carvajal RD, Alva A, Eaton K, Wang J, Liu Y, Yan X, Christensen J, Neuteboom S, Chao R, Pant S (2022). First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors. Invest New Drugs. (Read full article)
9. Dood R, Trabert B, Werner TL, Gaffney D, Jarboe E (2022). The time is now to start molecular subtyping high-intermediate and high-risk endometrial cancers. Int J Gynecol Cancer. (Read full article)
10. Dang C, Ewer MS, Delaloge S, Ferrero J, Colomer R, Cruz-Merino L, Werner TL, Dadswell K, Verrill M, Eiger D, Sarkar S, Haas S, Restuccia E, Swain S (2022). BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab. Cancers, 14(11), 2596.
11. Dang C, Ewer MS, Delaloge S, Ferrero JM, Colomer R, de la Cruz-Merino L, Werner TL, Dadswell K, Verrill M, Eiger D, Sarkar S, de Haas SL, Restuccia E, Swain SM (2022). BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. Cancers (Basel), 14(11). (Read full article)
12. Lheureux S, Matei DE, Konstantinopoulos PA, Wang BX, Gadalla R, Block MS, Jewell A, Gaillard SL, McHale M, McCourt C, Temkin S, Girda E, Backes FJ, Werner TL, Duska L, Kehoe S, Colombo I, Wang L, Li X, Wildman R, Soleimani S, Lien S, Wright J, Pugh T, Ohashi PS, Brooks DG, Fleming GF (2022). Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. J Immunother Cancer, 10(3). (Read full article)
13. Nath A, Cosgrove PA, Mirsafian H, Christie EL, Pflieger L, Copeland B, Majumdar S, Cristea MC, Han ES, Lee SJ, Wang EW, Fereday S, Traficante N, Salgia R, Werner T, Cohen AL, Moos P, Chang JT, Bowtell DDL, Bild AH (2021). Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer. Nat Commun, 12(1), 3039. (Read full article)
14. Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami PJ (2021). A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer, 21(1), 510. (Read full article)
15. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Liu J, Mahdi H, Martin L, Matei D, McHale M, McLean K, Miller DS, OMalley DM, Percac-Lima S, Ratner E, Remmenga SW, Vargas R, Werner TL, Zsiros E, Burns JL, Engh AM (2021). Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 19(2), 191-226. (Read full article)
16. Lee C, Werner TL, Deal AM, Krise-Confair CJ, Bentz TA, Cummings TM, Grant SC, Lee AB, Moehle J, Moffett K, Peck H, Williamson S, Zafirovski A, Shaw K, Hofacker JK (2020). Clinical Trial Metrics: The Complexity of Conducting Clinical Trials in North American Cancer Centers. JCO Oncol Pract, 17(1), e77-e93. (Read full article)
17. Tolcher AW, Kurzrock R, Valero V, Gonzalez R, Heist RS, Tan AR, Means-Powell J, Werner TL, Becerra C, Wang C, Leonowens C, Kalyana-Sundaram S, Kleha JF, Gauvin J, DAmelio AM Jr, Ellis C, Ibrahim N, Yan L (2020). Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. Cancer Chemother Pharmacol. (Read full article)
18. McComas KN, Torgeson AM, Ager BJ, Hellekson C, Burt LM, Maurer KA, Werner TL, Gaffney DK (2019). The variable impact of positive lymph nodes in cervical cancer: Implications of the new FIGO staging system. Gynecol Oncol, 156(1), 85-92. (Read full article)
19. Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA (2019). Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med, 381(25), 2403-2415. (Read full article)
20. Harris KL, Maurer KA, Jarboe E, Werner TL, Gaffney D (2019). LVSI positive and NX in early endometrial cancer: Surgical restaging (and no further treatment if N0), or adjuvant ERT? Gynecol Oncol, 156(1), 243-250. (Read full article)
21. Boothe D, Orton A, Kim J, Poppe MM, Werner TL, Gaffney DK (2019). Does Early Chemotherapy Improve Survival in Advanced Endometrial Cancer? Am J Clin Oncol, 42(11), 813-817. (Read full article)
22. Garrido-Laguna I, Krop I, Burris HA 3rd, Hamilton E, Braiteh F, Weise AM, Abu-Khalaf M, Werner TL, Pirie-Shepherd S, Zopf CJ, Lakshminarayanan M, Holland JS, Baffa R, Hong DS (2019). First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. Int J Cancer, 145(7), 1798-1808. (Read full article)
23. Mirza MR, vall Lundqvist E, Birrer MJ, dePont Christensen R, Nyvang GB, Malander S, Anttila M, Werner TL, Lund B, Lindahl G, Hietanen S, Peen U, Dimoula M, Roed H, r Knudsen A, Staff S, Krog Vistisen A, Bjrge L, Menp JU, AVANOVA investigators (2019). Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol, 20(10), 1409-1419. (Read full article)
24. Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA (2019). Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med, 381(25), 2403-2415. (Read full article)
25. Mirza MR, vall Lundqvist E, Birrer MJ, dePont Christensen R, Nyvang GB, Malander S, Anttila M, Werner TL, Lund B, Lindahl G, Hietanen S, Peen U, Dimoula M, Roed H, r Knudsen A, Staff S, Krog Vistisen A, Bjrge L, Menp JU, AVANOVA investigators (2019). Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol, 20(10), 1409-1419. (Read full article)
26. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, ElNaggar AC, Gershenson DM, Gray HJ, Hakam A, Jain A, Johnston C, Leath CA III, Liu J, Mahdi H, Matei D, McHale M, McLean K, OMalley DM, Penson RT, Percac-Lima S, Ratner E, Remmenga SW, Sabbatini P, Werner TL, Zsiros E, Burns JL, Engh AM (2019). NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. J Natl Compr Canc Netw, 17(8), 896-909. (Read full article)
27. Blackburn BE, Soisson S, Rowe K, Snyder J, Fraser A, Deshmukh V, Newman M, Smith K, Herget K, Kirchhoff AC, Kepka D, Werner TL, Gaffney D, Mooney K, Hashibe M (2019). Prognostic factors for rural endometrial cancer patients in a population-based cohort. BMC Public Health, 19(1), 921. (Read full article)
28. Francis SR, Ager BJ, Do OA, Huang YJ, Soisson AP, Dodson MK, Werner TL, Sause WT, Grant JD, Gaffney DK (2019). Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy. Gynecol Oncol, 154(1), 38-44. (Read full article)
29. Boothe D, Wolfson A, Christensen M, Francis S, Werner TL, Gaffney DK (2019). Lymphovascular Invasion in Endometrial Cancer: Prognostic Value and Implications on Adjuvant Radiation Therapy Use. Am J Clin Oncol, 42(7), 549-554. (Read full article)
30. Ager BJ, Francis SR, Do OA, Huang YJ, Soisson AP, Dodson MK, Werner TL, Sause WT, Grant JD, Gaffney DK (2019). Do vaginal recurrence rates differ among adjuvant vaginal brachytherapy regimens in early-stage endometrial cancer?LID - S1538-4721(18)30764-5 [pii]LID - 10.1016/j.brachy.2019.03.001 [doi]. Brachytherapy, 18(4), 453-461. (Read full article)
31. Berry S, Giraldo N, Nguyen P, Green B, Xu H, Ogurtsova A, Soni A, Succaria F, Wang D, Roberts C, Stein J, Engle E, Pardoll D, Anders R, Cottrell T, Taube JM, Tran B, Voskboynik M, Kuo J, Bang YL, Chung HC, Ahn MJ, Kim SW, Perera A, Freeman D, Achour I, Faggioni R, Xiao F, Ferte C, Lemech C, Meric-Bernstam F, Werner T, Hodi S, Messersmith W, Lewis N, Talluto C, Dostalek M, Tao A, McWhirter S, Trujillo D, Luke J, Xu C, BoMarelli, Qi J, Qin G, Yu H, Jenkins M, Lo KM, Halle JP, Lan Y, Taylor M, Vogelzang N, Cohn A, Stepan D, Shumaker R, Dutcus C, Stepan D, Guo M, Schmidt E, Taylor M, Vogelzang N, Di Simone C, Jain S, Richards D, Encarnacion C, Rasco D, Shumaker R, Dutcus C, Stepan D, Guo M, Schmidt E, Taylor M, Vogelzang N, Encarnacion C, Cohn A, Di Simone C, Rasco D, Richards D, Taylor M, Dutcus C, Stepan D, Shumaker R, Guo M, Schmidt E, Mier J, An J, Yang YY, Lee WH, Yang J, Kim JK, Kim HG, Paek SH, Lee JW, Woo J, Kim JB, Kwon H, Lim W, Paik NS, Kim YK, Moon BI, Janku F, Tan D, Martin-Liberal J, Takahashi S, Geva R, Gucalp A, Chen X, Subramanian K, Mataraza J, Wheler J, Bedard P (2019). Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). J Immunother Cancer.
32. Garrido-Laguna I, Krop I, Burris HA 3rd, Hamilton E, Braiteh F, Weise AM, Abu-Khalaf M, Werner TL, Pirie-Shepherd S, Zopf CJ, Lakshminarayanan M, Holland JS, Baffa R, Hong DS (2019). First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. Int J Cancer.
33. Soisson S, Ganz PA, Gaffney D, Rowe K, Snyder J, Wan Y, Deshmukh V, Newman M, Fraser A, Smith K, Herget K, Hanson HA, Wu YP, Stanford J, Al-Sarray A, Werner TL, Setiawan VW, Hashibe M (2018). Long-term Cardiovascular Outcomes Among Endometrial Cancer Survivors in a Large, Population-Based Cohort Study. J Natl Cancer Inst, 110(12), 1342-1351. (Read full article)
34. Gaffney DK, Hasibe M, Kepka D, Maurer KA, Werner TL (2018). Too many women are dying from cervix cancer: Problems and solutions. Gynecol Oncol.
35. Odei B, Boothe D, Suneja G, Werner TL, Gaffney DK (2017). Chemoradiation Versus Chemotherapy in Uterine Carcinosarcoma: Patterns of Care and Impact on Overall Survival. Am J Clin Oncol, 41(8), 784-791. (Read full article)
36. Young EL, Thompson BA, Neklason DW, Firpo MA, Werner T, Bell R, Berger J, Fraser A, Gammon A, Koptiuch C, Kohlmann WK, Neumayer L, Goldgar DE, Mulvihill SJ, Cannon-Albright LA, Tavtigian SV (2018). Pancreatic cancer as a sentinel for hereditary cancer predisposition. BMC Cancer, 18(1), 697. (Read full article)
37. Young EL, Thompson BA, Neklason DW, Firpo MA, Werner T, Bell R, Berger J, Fraser A, Gammon A, Koptiuch C, Kohlmann WK, Neumayer L, Goldgar DE, Mulvihill SJ, Cannon-Albright LA, Tavtigian SV (2018). Pancreatic cancer as a sentinel for hereditary cancer predisposition. BMC Cancer, 18(1), 697. (Read full article)
38. Park J, Blackburn BE, Rowe K, Snyder J, Wan Y, Deshmukh V, Newman M, Fraser A, Smith K, Herget K, Burt L, Werner T, Gaffney DK, Lopez AM, Mooney K, Hashibe M (2018). Rural-metropolitan disparities in ovarian cancer survival: a statewide population-based study. Ann Epidemiol, 28(6), 377-384. (Read full article)
39. Werner TL, Sachdev J, Swisher EM, Gutierrez M, Kittaneh M, Stein MN, Xiong H, Dunbar M, Sullivan D, Komarnitsky P, McKee M, Tan AR (2018). Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study. Cancer Med, 7(6), 2360-2369. (Read full article)
40. Park J, Blackburn BE, Rowe K, Snyder J, Wan Y, Deshmukh V, Newman M, Fraser A, Smith K, Herget K, Burt L, Werner TL, Gaffney DK, Lopez A, Mooney A (2018). Rural-metropolitan disparities in ovarian cancer survival: A statewide population-based study. Ann Epidemiol.
41. Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, Colomer R, Vieira C, Werner TL, Douthwaite H, Bradley D, Waldron-Lynch M, Kiermaier A, Eng-Wong J, Dang C, BERENICE Study Group (2017). Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol, 29(3), 646-653. (Read full article)
42. Soisson S, Ganz PA, Gaffney D, Rowe K, Snyder J, Wan Y, Deshmukh V, Newman M, Fraser A, Smith K, Herget K, Hanson HA, Wu YP, Stanford J, Werner TL, Setiawan VW, Hashibe M (2018). Long-term, adverse genitourinary outcomes among endometrial cancer survivors in a large, population-based cohort study. Gynecol Oncol, 148(3), 499-506. (Read full article)
43. Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, Colomer R, Vieira C, Werner TL, Douthwaite H, Bradley D, Waldron-Lynch M, Kiermaier A, Eng-Wong J, Dang C (2018). Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol, 29(3), 646-653. (Read full article)
44. Brady SW, McQuerry JA, Qiao Y, Piccolo SR, Shrestha G, Jenkins DF, Layer RM, Pedersen BS, Miller RH, Esch A, Selitsky SR, Parker JS, Anderson LA, Dalley BK, Factor RE, Reddy CB, Boltax JP, Li DY, Moos PJ, Gray JW, Heiser LM, Buys SS, Cohen AL, Johnson WE, Quinlan AR, Marth G, Werner TL, Bild AH (2018). Publisher Correction: Combating subclonal evolution of resistant cancer phenotypes. Nat Commun, 8(1), 1231.
45. Taurin S, Yang CH, Reyes M, Cho S, Coombs DM, Jarboe EA, Werner TL, Peterson CM, Janat-Amsbury MM (2018). Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model. Int J Gynecol Cancer, 28(1), 152-160. (Read full article)
46. Werner TL, Ray A, Lamb JG, VanBrocklin M, Hueftle K, Cohen AL, Beck AC, Buys SS, Dyess DL, Butler TW, Dumlao TL, Neumayer L, Khong HT (2017). A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer. Clin Breast Cancer, 17(7), 503-509. (Read full article)
47. Brady SW, McQuerry JA, Qiao Y, Piccolo SR, Shrestha G, Jenkins DF, Layer RM, Pedersen BS, Miller RH, Esch A, Selitsky SR, Parker JS, Anderson LA, Dalley BK, Factor RE, Reddy CB, Boltax JP, Li DY, Moos PJ, Gray JW, Heiser LM, Buys SS, Cohen AL, Johnson WE, Quinlan AR, Marth G, Werner TL, Bild AH (2017). Combating subclonal evolution of resistant cancer phenotypes. Nat Commun, 8(1), 1231. (Read full article)
48. Mackay DR, Howa AC, Werner TL, Ullman KS (2017). Nup153 and Nup50 promote recruitment of 53BP1 to DNA repair foci by antagonizing BRCA1-dependent events. J Cell Sci, 130(19), 3347-3359. (Read full article)
49. Boothe D, Williams N, Odei B, Poppe MM, Werner TL, Suneja G, Gaffney DK (2017). The Addition of Adjuvant Chemotherapy to Radiation in Early-Stage High-Risk Endometrial Cancer: Survival Outcomes and Patterns of Care. Int J Gynecol Cancer, 27(5), 912-922. (Read full article)
50. Cohen AL, Neumayer L, Boucher K, Factor RE, Shrestha G, Wade M, Lamb JG, Arbogast K, Piccolo SR, Riegert J, Schabel M, Bild AH, Werner TL (2017). Window-of-Opportunity Study of Valproic Acid in Breast Cancer Testing a Gene Expression Biomarker. JCO Precis Oncol, 1. (Read full article)
51. Odei B, Boothe D, Suneja G, Werner TL, Gaffney DK (2017). Chemoradiation Versus Chemotherapy in Uterine Carcinosarcoma: Patterns of Care and Impact on Overall Survival [Epub ahead of Print]. Am J Clin Oncol.
52. Willmore-Payne C, Damjanovich-Colmenares K, Pasi AV, Werner TL, Gulbahce HE, Downs-Kelly E, Geiersbach KB (2016). Inconsistent Results With Different Secondary Reflex Assays for Resolving HER2 Status. Am J Clin Pathol, 146(5), 618-626. (Read full article)
53. Bailey H, McPherson JP, Bailey EB, Werner TL, Gupta S, Batten J, Reddy G, Bhat G, Sharma S, Agarwal N (2016). A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors. Cancer Chemother Pharmacol, 78(5), 1059-1071. (Read full article)
54. Willmore-Payne C, Damjanovich-Colmenares K, Pasi AV, Werner TL, Gulbahce HE, Downs-Kelly E, Geiersbach KB (2016). Inconsistent Results With Different Secondary Reflex Assays for Resolving HER2 Status. Am J Clin Pathol, 146(5), 618-626. (Read full article)
55. Geiersbach KB, Willmore-Payne C, Pasi AV, Paxton CN, Werner TL, Xu X, Wittwer CT, Gulbahce HE, Downs-Kelly E (2016). Genomic Copy Number Analysis of HER2-Equivocal Breast Cancers. Am J Clin Pathol, 146(4), 439-47. (Read full article)
56. Patnaik A, Tolcher A, Papadopoulos KP, Beeram M, Rasco D, Werner TL, Bauman JW, Scheuber A, Cox DS, Patel BR, Zhou Y, Hamid M, Schramek D, Sharma S (2016). Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours. Cancer Chemother Pharmacol, 78(3), 491-500. (Read full article)
57. Morgan RJ Jr, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, Copeland L, Crispens MA, DeRosa M, Dorigo O, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, OMalley DM, Penson RT, Percac-Lima S, Pineda M, Plaxe SC, Powell MA, Ratner E, Remmenga SW, Rose PG, Sabbatini P, Santoso JT, Werner TL, Burns J, Hughes M (2016). Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 14(9), 1134-63. (Read full article)
58. Boothe D, Orton A, Odei B, Stoddard G, Suneja G, Poppe MM, Werner TL, Gaffney DK (2016). Chemoradiation versus chemotherapy or radiation alone in stage III endometrial cancer: Patterns of care and impact on overall survival. Gynecol Oncol, 141(3), 421-427. (Read full article)
59. Geiersbach K, Willmore-Payne C, Pasi Av, Paxton C, Werner TL, Xu X, Wittwer CT, Gulbahce HE, Downs-Kelly E (2016). Genomic Copy Number Analysis of HER2-Equivocal Breast Cancers. Am J Clin Pathol, Oct;146(4), 439-47.
60. Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R (2016). First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res, 22(8), 1932-9. (Read full article)
61. Camp NJ, Lin W, Bigelow A, Burghel GJ, Mosbruger T, Parry M, Waller R, Rigas SH, Rajamanickam V, Cosby R, Brock IW, Jones B, Connley D, Sargent R, Wang G, Cannon-Albright LA, Werner TL, Factor RE, Bernard P, Knight S, Abo R, Reed MWR, Gertz J, Cox A (2016). Discordant Haplotype Sequencing Identifies Candidate Functional Variants from Disease-Association studies: Breast Cancer Risk at 2q33. doi: 10.1158/0008-5472.CAN-15-1629. PMID: 26795348. Cancer Res, 76(7), 1916-25.
62. Agarwal N, McPherson JP, Bailey H, Gupta S, Werner TL, Reddy G, Bhat G, Bailey EB, Sharma S (2016). A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin. Cancer Chemother Pharmacol, 77(2), 299-308. (Read full article)
63. Werner TL, Wade ML, Agarwal N, Boucher K, Patel J, Luebke A, Sharma S (2015). A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-beta, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort. Invest New Drugs, 33(6), 1217-24. (Read full article)
64. Moore KN, Sill MW, Tenney ME, Darus CJ, Griffin D, Werner TL, Rose PG, Behrens R (2015). A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial. Gynecol Oncol, 138(3), 513-8. (Read full article)
65. Lum MM, Belnap TW, Frandsen J, Brown AP, Sause WT, Soisson AP, Dodson MK, Werner T, Gaffney DK (2013). Survival Analysis of Cancer Patients With FIGO Stage IIIA Endometrial Cancer. Am J Clin Oncol, 38(3), 283-8. (Read full article)
66. Lum MM, Belnap TW, Frandsen J, Brown AP, Sause WT, Soisson AP, Dodson MK, Werner T, Gaffney DK (2015). Survival Analysis of Cancer Patients With FIGO Stage IIIA Endometrial Cancer. Am J Clin Oncol, 38(3), 283-8. (Read full article)
67. Diamond JR, Wu B, Agarwal N, Bowles DW, Lam ET, Werner TL, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S (2015). Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors. Invest New Drugs, 33(3), 691-9. (Read full article)
68. Grenache DG, Heichman KA, Werner TL, Vucetic Z (2015). Clinical performance of two multi-marker blood tests for predicting malignancy in women with an adnexal mass. Clin Chim Acta, 438, 358-63. (Read full article)
69. Dizon DS, Mackay HJ, Thomas GM, Werner TL, Kohn EC, Hess D, Rose PG, Covens AL (2014). State of the science in cervical cancer: where we are today and where we need to go. Cancer, 120(15), 2282-8. (Read full article)
70. Yadav BS, George P, Sharma SC, Gorsi U, McClennan E, Martino MA, Chapman J, Chen LM, Prakash G, Malhotra P, Tantravahi SK, Glenn MJ, Werner TL, Baksh K, Sokol L, Morris GJ (2014). Primary non-Hodgkin lymphoma of the ovary. Semin Oncol, 41(3), e19-30. (Read full article)
71. Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, OMalley DM, Penson RT, Powell MA, Remmenga SW, Sabbatini P, Santoso JT, Schink JC, Teng N, Werner TL, Dwyer MA, Hughes M (2013). Ovarian cancer, version 2.2013. J Natl Compr Canc Netw, 11(10), 1199-209. (Read full article)
72. Horvath LE, Werner T, Boucher K, Jones K (2013). The relationship between tumor size and stage in early versus advanced ovarian cancer. Med Hypotheses, 80(5), 684-7. (Read full article)
73. Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, OMalley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA, National Comprehensive Cancer Network (2012). Ovarian cancer, version 3.2012. J Natl Compr Canc Netw, 10(11), 1339-49. (Read full article)
74. Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, OMalley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA (2012). Ovarian cancer, version 3.2012. J Natl Compr Canc Netw, 10(11), 1339-49. (Read full article)
75. Albright F, Teerlink C, Werner TL, Cannon-Albright LA (2012). Significant evidence for a heritable contribution to cancer predisposition: a review of cancer familiality by site. BMC Cancer, 12, 138. (Read full article)
76. Morgan RJ Jr, Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray HJ, Grigsby PW, Hakam A, Havrilesky LJ, Johnston C, Lele S, Matulonis UA, OMalley DM, Penson RT, Remmenga SW, Sabbatini P, Schilder RJ, Schink JC, Teng N, Werner TL (2011). Epithelial ovarian cancer. J Natl Compr Canc Netw, 9(1), 82-113. (Read full article)
77. Brown AP, Neeley ES, Werner T, Soisson AP, Burt RW, Gaffney DK (2010). A population-based study of subsequent primary malignancies after endometrial cancer: genetic, environmental, and treatment-related associations. Int J Radiat Oncol Biol Phys, 78(1), 127-35. (Read full article)
78. Montejo M, Werner TL, Gaffney D (2009). Current challenges in clinical management of endometrial cancer. Adv Drug Deliv Rev, 61(10), 883-9. (Read full article)
79. Werner TL, Agarwal N, Carney HM, Rodgers GM (2007). Management of cancer-associated thrombotic microangiopathy: what is the right approach? Am J Hematol, 82(4), 295-8. (Read full article)
80. Lo T, van Der Schalie E, Werner T, Brun YV, Din N (2004). A temperature-sensitive mutation in the dnaE gene of Caulobacter crescentus that prevents initiation of DNA replication but not ongoing elongation of DNA. J Bacteriol, 186(4), 1205-12. (Read full article)

Review

1. Sama S, Rosqvist S, Savage T, Lomo L, Sibbald K, Straubhar A, Werner TL (2024). Durable response to BRAF inhibitor monotherapy in recurrent metastatic low grade serous ovarian cancer. [Review]. Gynecol Oncol Rep, 53, 101412. (Read full article)
2. Gaffney DK, Hashibe M, Kepka D, Maurer KA, Werner TL (2018). Too many women are dying from cervix cancer: Problems and solutions. [Review]. Gynecol Oncol, 151(3), 547-554. (Read full article)
3. Williams NL, Werner TL, Jarboe EA, Gaffney DK (2015). Adenocarcinoma of the cervix: should we treat it differently? [Review]. Curr Oncol Rep, 17(4), 17. (Read full article)
4. Williams NL, Werner TL, Jarboe EA, Gaffney DK (2015). Adenocarcinoma of the cervix: should we treat it differently? [Review]. Curr Oncol Rep, 2015 Apr, 17(4):17.
5. Lim HY, Werner T, Agarwal N, Rodgers GM (2008). Management of thrombotic microangiopathy with underlying malignancy. Helix Review Series: Oncology. 2008; 13(2):18-21. [Review]. 13(2), 18-21.
6. Copur MS, Ledakis P, Bolton M, Morse AK, Werner T, Norvell M, Muhvic J, Chu E (2002). An adverse interaction between warfarin and capecitabine: a case report and review of the literature. [Review]. Clin Colorectal Cancer, 1(3), 182-4. (Read full article)

Book Chapter

1. Werner TL (December 2015). Chapter 4 - Breast Cancer Bone Metastases. In R. Lor Randall (Ed.), Metastatic Bone Disease: Essentials for the Orthopedic Surgeon (pp. 45-54). Springer International.

Conference Proceedings

1. Dang C, Ewer MS, Delaloge S, Ferrero JM, Verrill M, Colomer R, Vieira C, de la Cruz Merino L, Lucas J, Werner TL, Douthwaite H, Bradley D, Waldron-Lynch M, Eng-Wong J, Swain SM (2017). Safety of adjuvant treatment with pertuzumab plus trastuzumab after neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive localized breast cancer: Updated results from the BERENICE study. 2017 San Antonio Breast Cancer Symposium.

Case Report

1. Tantravahi SK, Werner TL (2012). Locally recurrent endometrial cancer: a case report. J Natl Compr Canc Netw, 10(4), 442-5. (Read full article)
2. Wong J, Werner TL (July 2011). Kikuchi-Fujimoto Lymphadenitis: A Case of Misdiagnosed Breast Cancer. Am J Case Rep, 12, 80-82.
3. Agarwal N, Spahr JE, Werner TL, Newton DL, Rodgers GM (2006). Acquired amegakaryocytic thrombocytopenic purpura. Am J Hematol, 81(2), 132-5. (Read full article)

Letter

1. Camp NJ, Werner TL, Cannon-Albright LA (2008). Familial myeloma. [Letter to the editor]. N Engl J Med, 359(16), 1734-5; author reply 1735. (Read full article)

Abstract

1. Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami PJ (2021). A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. https://doi.org/10.1186/s12885-021-08242-4 [Abstract]. 21, 510.
2. Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Ben-Baruch N, Werner TL, Oaknin A, Nam JH, Leath CA, Nicum S, Cella D, Sullivan DM, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA (2019). VELIA/GOG-3005: Integration of veliparib with front-line chemotherapy+maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin [Abstract]. 30, 895-896.
3. Kingsford R, Pitt D, Low S, Weaver L, Moehle J, Cohen Al, Werner TL (2018). How to Be a Principal Investigator: Developing and Implementing of a Practical Training Program [Abstract]. 10th Annual AACI CRI Meeting Abstract Template.
4. Pant S, Spira AI, Cho SBC, Goel S, Hoimes CJ, Alva AS, Balaraman R, Bauer TM, Lowry PA, Ramaekers RC, Siegel RD, Werner TL, Tannir NM, Faltaos D, Potvin D, Neuteboom ST, Christensen J, Chao RC, Kyriakopoulos C (2018). Evalution of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT) [Abstract]. J Clin Oncol, 36.
5. Cohen AL, Neumayer L, Boucher K, Factor R, Shtrestha G, Wade M, Lamb G, Arbogast Ky, Piccolo S, Riegert J, Schabel M, Bild A, Werner TL (4/2017). A Window of Opportunity Study of Valproic Acid in Breast Cancer Testing a Gene Expression Biomarker [Abstract]. JCO Precision Oncology, 1(April 2017), 1-11.
6. Cohen A, Neumayer L, Factor R, Boucher K, Wade ML, Lamb JG, Arbogast K, Piccolo S, Shrestha G, Riegert J, Schabel M, Bild A, Werner TL (2016). A phase 1 window of opportunity study of valproic acid (VPA) in breast cancer testing a gene expression biomarker. [Abstract]. J Clin Oncol, 2016 ASCO Annual Meeting, 34(2016), suppl;abst 1084.
7. Bauer T, Adkins D, Schwartz GK, Werner TL, Alva AS, Hong DS, Carvaja RD, Saleh MN, Bazhenova L, Goel S, Eaton KD, Siegel RD, Wang D, Lauer RC, Neuteboom STC, Faltaos D, Chen I, Christensen J, Chao RC, Heist RS (2016). A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors. [Abstract]. J Clin Oncol, 2016 ASCO Annual Meeting, 34(2016), suppl;abstr 2575.
8. Werner T, Sachdev J, Swisher E, Gutierrez M, Kittaneh M, Stein M, Xiong H, Dunbar M, Sullivan D, Ansell P, Hetman R, Komarnitsky P, McKee M, Tan A (2016). Veliparib (ABT-888) extended-release formulations: a phase 1 study on safety, pharmacokinetics (PK), and bioavailability in patients with advanced solid tumors. [Abstract]. J Clin Oncol, 2016 ASCO Annual Meeting, 34(2016), suppl;abstr 2579.
9. Boothe D, Williams, N, Odel B, Poppe M, Werner TL, Suneja G, Gaffney D (2016). The addition of adjuvant chemotherapy to radiation in high risk endometrial cancer: Survival outcomes and patterns of care. [Abstract]. J Clin Oncol, 2016 ASCO Annual Meeting, 34(2016), suppl;abstr 5587.
10. Munster P, VanDer Noll R, Voest E, Specht J, Werner TL, Dees EC, Tan AR, Daud A, Schellens J, Lolkema MP, Griffin M, Agarwal N, Falchook GS, Kleha JF, Durante M, Smith DA, Adams L, Greshock J, Morris SR, Kurzrock R (2015). PI3K kinase inhibitor GSK2126458 (GSK458): Clinical activity in select patient (pt) populations defined by predictive markers (Study P3K112826). Oral Presentation European Society of Medical Oncology, September 2012, Vienna, Austria. [Abstract]. European Society of Medical Oncology. [Abstract]. Clinical Cancer Research.
11. Moore KN, Sill MW, Tenney ME, Darus CJ, Griffin D, Werner TL, Rose PG, Behrens R (2015). A Phase II Trial of Trebananib (AMG 386; IND#111071), a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients with Persistent/Recurrent Carcinoma of the Endometrium: A Gynecologic Oncology Group Study [Abstract]. SGO March 2015, 137(supp 1), 24.
12. Diamond JR, Agarwal N, Bowles DW, Lan ET, Werner TL, Wu B, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S (2014). Evaluation of pharmacokinetic (PK) drug-drug interactions (DDI) between trebananib and paclitaxel (PTX) in patients (pts) with advanced solid tumors [Abstract]. ASCO Annual Meeting, 2014, Chicago, Illinois.
13. Cohen AL, Factor R, Schabel M, Bild A, Werner TL (2013). Effect of short course, high-dose valproic acid on proliferation in breast adenocarcinomas. [Abstract]. Journal of Clinical Oncology, 2013 ASCO Annual Meeting Abstracts 31:15s, 2013(May 20 Supplement), e13522.
14. Gaffney DK, Werner TL (2012). Curative Treatment for Recurrent and Metastatic Cervical Cancer [Abstract]. Expert Rev Obstet Gynecol, 7(6), 521-523.
15. Smit WS, Sufliarsky J, Werner TL, Dizon D, Wagnerova M, Hirte HW, Spirtos N, Oza A, Dirix L, El-Hashimy M, Acharyya S, Tan EY, Weber D, Schellens JH (2012). A phase II study of Patupilone (EPO906) in patients with platinum- resistant or -refractory ovarian cancer. January 2012. [Abstract]. Clin Ovarian Cancer Other Gynecol Malig.
16. Agarwal, N, Sahu M, Abhyankar J, Werner TL, Benjamin B, Srinivas NR, Sharma S (June 2011). A drug-drug interaction study of Everolimus (an mTOR inhibitor) and JI-101, an orally active inhibitor of VEGF2, PDGF, and EphB4 receptors, in patients with advanced urologic tumors. American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, June 2011. Published in J Clin Oncol 29:15s, 2011 (suppl; abstr e15077). [Abstract]. Journal of Clinical Oncology, 29(15s).
17. Cohen, AL, Schabel M, Bild AH, Werner TL (2011). VAST (Valproic Acid Signature Trial): A proof-of-principle study correlating pharmacology, pathology, and advanced imaging with genomic prediction of drug sensitivity in breast cancer. Poster Presentation Oncology Annual Meeting, Chicago, Illinois, June 2011. (suppl; abstr TPS148) [Abstract]. J Clin Oncol, 29(15s).
18. Bild AH, Sun Y, Soldi R, Conner T, Walker D, Werner T, Spira A, Andrulis I, Buys SS, Johnson E (2009). A Genomic Biomarker for Breast Cancer Development in High-Risk Women. Poster Presentation. CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2009. Published in Cancer Res 2009; 69(Suppl.): (24). Dec 15, 2009. [Abstract]. Cancer Res, 69(24).
19. Smit WM, Sufliarksy J, Werner TL, Dizon D, Wagnerova M, Hirte HW, Delaney R, Li J, Weber D, Schellens JH (2009). A phase II study evaluating the safety and efficacy of Patupilone in patients with platinum refractory/resistant ovarian, primary fallopian, or peritoneal cancer. Poster Presentation. American Society of Clinical Oncology Annual Meeting, Orlando, Florida, May 2009. Published in J Clin Oncol 27:15s, 2009 (suppl; abstr 5563). [Abstract]. Journal of Clinical Oncology, 27(15s), 5563.
20. Horvath LE, Werner T, Jones K (2007). The Relationship between Tumor Size and Stage in Early versus Advanced Ovarian Cancer: A Retrospective Chart Review. Poster Presentation. American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, June 2007. Published in J Clin Oncol, 25:18s, 2007 (suppl; abstr 5580). [Abstract]. Journal Of Clinical Oncology, 25(18s), 5580.

Other

1. Berry S, Giraldo N, Nguyen P, Green B, Xu H, Ogurtsova A, Soni A, Succaria F, Wang D, Roberts C, Stein J, Engle E, Pardoll D, Anders R, Cottrell T, Taube JM, Tran B, Voskoboynik M, Kuo J, Bang YL, Chung HC, Ahn MJ, Kim SW, Perera A, Freeman D, Achour I, Faggioni R, Xiao F, Ferte C, Lemech C, Meric-Bernstam F, Werner T, Hodi S, Messersmith W, Lewis N, Talluto C, Dostalek M, Tao A, McWhirter S, Trujillo D, Luke J, Xu C, BoMarelli, Qi J, Qin G, Yu H, Jenkins M, Lo KM, Halle JP, Lan Y, Taylor M, Vogelzang N, Cohn A, Stepan D, Shumaker R, Dutcus C, Guo M, Schmidt E, Rasco D, Brose M, Vogelzang N, Di Simone C, Jain S, Richards D, Encarnacion C, Rasco D, Shumaker R, Dutcus C, Stepan D, Guo M, Schmidt E, Taylor M, Vogelzang N, Encarnacion C, Cohn A, Di Simone C, Rasco D, Richards D, Taylor M, Dutcus C, Stepan D, Shumaker R, Guo M, Schmidt E, Mier J, An J, Yang YY, Lee WH, Yang J, Kim JK, Kim HG, Paek SH, Lee JW, Woo J, Kim JB, Kwon H, Lim W, Paik NS, Kim YK, Moon BI, Janku F, Tan D, Martin-Liberal J, Takahashi S, Geva R, Gucalp A, Chen X, Subramanian K, Mataraza J, Wheler J, Bedard P (2019). Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). J Immunother Cancer (7(1), p. 46). England. (Read full article)

News

• Defining the Role of the CTO Medical Director at AACI Cancer Centers
• Theresa L. Werner, MD, on Ovarian Cancer and the Immunotherapy Revolution
• Theresa L. Werner, MD: Talking With Patients About Ovarian Cancer Clinical Trials
• AACI Commentary
• Commentary by Theresa L. Werner, MD, Ovarian Cancer Site Editor for JNCCN 360
• Association of American Cancer Institutes

Huntsman Cancer Institute News

• 8 Silent Signs of Ovarian Cancer
• Giving Endometrial Cancer Patients a Voice
• Letter of Hope from Theresa Werner, Senior Director of Clinical Research
• Bringing Cancer Clinical Trials to Rural Communities
• A Lifelong Connection between Ovarian Cancer Patient and Her Doctor: 10 Years Later
• Ovarian Cancer Risk Factors, Screening, and Treatment
• Proton Therapy Provides Hope to Local Artist with Brain Tumor
• Uterine Cancer Risk Factors, Screening, and Treatment
• Theresa Werner, MD, on the Importance of the HPV Vaccine and Cervical Cancer Screening
• Talks with Docs: Theresa Werner, MD

Podcasts

• The Importance of Cancer Clinical Trials and How You Can Get Involved
• The Misconception of "Preventative" Chemotherapy
• Spotting Signs of Abdominal Cancer